Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,836 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+ - NCT04689347RecruitingPhase 1/Phase 2
New chemotherapy and targeted drug for a specific colon cancer type
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
Milan, MilanAges 18–75 - NCT03829254RecruitingPhase 1/Phase 2
NUC-7738 treatment for advanced solid cancers and lymphoma
This early-phase study tests how safe NUC-7738 is and how it works in people with advanced solid tumors and certain lymphomas. Some participants may also receive pembrolizumab for specific cancers, aiming to improve cancer control while carefully monitoring side effects.
CambridgeAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
A new drug combo for advanced cancers
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Gilbert, ArizonaAges 18–70 - NCT04623502Recruiting
Study of kidney and bladder cancer metabolism during surgery
This study looks at how kidney and bladder (urothelial) tumors use fuel by taking samples during surgery or biopsy. It may help researchers learn what drives these cancers and guide better future treatments.
Dallas, TexasAges 18 years+ - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Tampa, FloridaAges 18 years+ - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Birmingham, AlabamaAges 2–21 - NCT04199026Recruiting
Tiny implanted device delivers drugs to sarcoma tumors
This trial tests an implantable device placed during planned surgery to deliver cancer medicines directly to sarcoma tumors and study how they affect the tumors. It may be an option if your sarcoma has come back or spread and surgery is part of standard care.
Houston, TexasAges 10 years+ - NCT04222062RecruitingPhase 2
Compare Gliadel implant versus focused brain radiation
This Phase 2 study compares two ways to treat brain metastases: a Gliadel wafer placed during planned surgery versus focused stereotactic radiosurgery. It aims to see which approach works better and is safer for people with a limited number of brain tumor spots.
Detroit, MichiganAges 18 years+ - NCT04048278RecruitingEarly Phase 1
Lidocaine IV infusion for pancreatic cancer treatment
This early-phase study tests whether giving lidocaine through an IV infusion can help treat pancreatic cancer. It will enroll people with confirmed pancreatic cancer that can be measured on scans, including some cases discovered to have spread during surgery.
Chicago, IllinoisAges 18 years+ - NCT04085029Recruiting
Study registry for patients getting focused radiation for spread disease
This study keeps a registry (a record) of people with metastatic (spread) cancer who are receiving focused, high-dose radiation to body sites outside the brain. It aims to better understand outcomes and care patterns for these patients.
Cary, North CarolinaAges 18 years+ - NCT04068649RecruitingPhase 2
Single high-dose radiation vs standard palliative radiation
This Phase 2 study compares a one-time, high-dose radiation treatment (SBRT) with the usual, shorter-course palliative radiation. The goal is to see which approach better relieves symptoms from metastatic (spread) cancer.
Buffalo, New YorkAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT03977571Recruiting
Surgery plus cancer drugs for kidney cancer that spread
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Aarhus, Central Region of DenmarkAges 18 years+ - NCT03750227RecruitingPhase 3
Radiation before or after brain tumor surgery
This study compares giving focused, high-precision radiation before or after surgery for brain metastases. It aims to see which timing works best to control tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT03808337RecruitingPhase 2
SBRT radiation plus standard treatment for spread cancer
This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.
San Carlos, CaliforniaAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT03647358RecruitingPhase 1
Iodine scan planning for metastatic thyroid cancer treatment
This early-stage study tests how well a special iodine scan (using iodine-124) can help plan treatment with radioactive iodine (iodine-131) for thyroid cancer that has spread. It may help doctors decide the right way to measure and target radioiodine-avid (radioiodine-absorbing) metastases.
New York, New YorkAges 18 years+ - NCT03250078Recruiting
Pancreatic cancer screening for people at high genetic risk
This study offers pancreatic cancer screening for people with strong family history or certain inherited gene changes. It may help find pancreatic cancer earlier, when treatment may be more effective.
Norwalk, ConnecticutAges 50–90 - NCT03099356RecruitingPhase 2
Cyclophosphamide and sirolimus for thyroid cancer that won’t respond to iodine
This trial tests whether the combination of cyclophosphamide and sirolimus can slow or shrink metastatic thyroid cancer that does not respond to iodine-131. It may help people whose cancer can’t be cured with surgery or other standard options and is still growing.
Ann Arbor, MichiganAges 18 years+ - NCT03275311Recruiting
Care approach changes for metastatic breast cancer
This trial looks at how treatment care for metastatic breast cancer has evolved over time. You may be eligible if you are an adult receiving active cancer treatment in a comprehensive cancer center in France.
AngersAges 18 years+ - NCT03161522RecruitingPhase 2
Chemo alone versus with radiation or surgery for limited spread
This study tests whether adding radiation or surgery to chemotherapy can improve outcomes for people whose esophageal or stomach cancer has spread to only a few places. If your cancer is “oligometastatic” (up to 3 spots), the trial helps doctors see which approach gives the best control.
Houston, TexasAges 18–79
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,836 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.